MEGAN BLEWETT

Megan Blewett is currently an investor at Scion Life Sciences, where she focuses on biotechnology and therapeutics. Prior to her current role, she served as the co-founder and President of Iris Medicine and co-founded Kelonia Therapeutics, a company developing tissue-specific gene therapies. She previously worked as a venture capital investor at Venrock and currently holds board positions at Convergent Research and Pioneer Labs. Blewett earned an AB and AM from Harvard University and a PhD in chemistry from The Scripps Research Institute, where her doctoral research contributed to Vividion Therapeutics, which Bayer acquired in 2021. Her industry recognition includes being named to the Forbes 30 Under 30 list for Healthcare and the Business Insider Under 40 in Biotech list. Her career centers on advancing genetically targeted treatments for neurodegenerative disorders and scaling early-stage life sciences companies.